Cas:227958-47-6 methyl 3-[(2-bromoacetyl)amino]thiophene-2-carboxylate manufacturer & supplier

Chemical Name:methyl 3-[(2-bromoacetyl)amino]thiophene-2-carboxylate

CAS.NO:227958-47-6

Synonyms:3-(2-bromoacetylamino)thiophene-2-carboxylic acid methyl ester

Molecular Formula:C₈H₈BrNO₃S

Molecular Weight:278.12300

HS Code:2934999090

Physical and Chemical Properties:

Melting point:91 ℃

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:83.64000

Exact Mass:276.94100

LogP:1.94110

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-(2-bromoacetylamino)thiophene-2-carboxylic acid methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(2-bromoacetylamino)thiophene-2-carboxylic acid methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(2-bromoacetylamino)thiophene-2-carboxylic acid methyl ester Use and application,3-(2-bromoacetylamino)thiophene-2-carboxylic acid methyl ester technical grade,usp/ep/jp grade.

Related News: It’s official. Nearly two years after the FDA granted conditional approval to Merck’s Keytruda and Eisai’s Lenvima for endometrial cancer, the U.S. regulator has blessed the combination therapy, with no strings attached. 2-(5-(4-bromobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid manufacturers The growing use of biocatalysis in pharmaceutical chemistry promises to deliver on this need, while also offering substantial cost savings and faster time to market for urgently needed therapeutics. 1-Butanaminium, 4-amino-N,N-dimethyl-N-[2-(tetradecyloxy)ethyl]- suppliers Biogen’s Alzheimer’s drug, Aduhelm, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug. Methanol, [3-(1-piperidinylmethyl)phenoxy]- vendor & factory As we expand our offering into the US and beyond, NOVA aims to become the go-to partner for pharma and biotech companies for in silico clinical trial support. I am delighted to welcome Grégoire to the Novadiscovery team and look forward to working closely with him.”,As we expand our offering into the US and beyond, NOVA aims to become the go-to partner for pharma and biotech companies for in silico clinical trial support. I am delighted to welcome Grégoire to the Novadiscovery team and look forward to working closely with him.”